With nearly 60,000 employees working in this industry cluster, including healthcare workers, it is one of the strongest in the region. With world class institutional and academic assets to leverage, this region has become a focus of biomedical expertise and development.

To support the development of convenient, accurate diagnostics and potential therapeutics for COVID-19, we can anticipate an increase in NIH funding to Yale University. NIH Funding in 2020 was $568M. Given the higher costs of care associated with patients with underlying health issues, continued R&D is needed for existingdiseases. We have a number of early-stage and mature bioscience companies working on treatmentsfor co-morbidities such as diabetes, high blood pressure, cancer and more.

In 2020, the following Greater New Haven companies received funding from the National Institute of Public Health: